Home / Precision Medicine

Precision Medicine

International Team Discovers Unique Pathway for Treating Deadly Children’s Brain Cancer

PHOENIX, Ariz. — Aug. 22, 2019 — An international team of researchers led by Yale University, University of Iowa, and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, has discovered a new pathway that may improve success against an incurable type of children’s brain cancer. The …

Read More »

FDA Approves Genentech’s Rozlytrek for Patients with ROS1-Positive Metastatic NSCLC and NTRK Gene Fusion-Positive Solid Tumors

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Rozlytrek™ (entrectinib) for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer (NSCLC). The FDA has also granted accelerated approval to …

Read More »

Onconova Therapeutics and Mission Bio Partner to Advance Precision Oncology Clinical Trials Employing Single-Cell Genomics

NEWTOWN, Pa. and SOUTH SAN FRANCISCO, Calif., Aug. 12, 2019 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on Myelodysplastic Syndromes (MDS), and Mission Bio, the pioneer in targeted single-cell DNA analysis and precision genomics, …

Read More »

FDA Accepts Blueprint’s NDA for Avapritinib for the Treatment of PDGFRA Exon 18 Mutant GIST and Fourth-Line GIST

CAMBRIDGE, Mass., Aug. 7, 2019 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) for avapritinib for the treatment of …

Read More »

Syapse and Pfizer Collaborate in Oncology Precision Medicine Focused on Outcomes Research Using Real-World Evidence

SAN FRANCISCO, July 23, 2019 (GLOBE NEWSWIRE) — Syapse, a company accelerating precision medicine through insights derived from its global health system network, today announced that it has entered into a strategic collaboration with Pfizer Inc. (NYSE: PFE) to advance cancer outcomes research using real-world evidence toward the ultimate goal …

Read More »

New Research Identifies Gene that Hides Cancer Cells from Immunotherapy

SEATTLE — July 18, 2019 — A team at Fred Hutchinson Cancer Research Center has identified a gene that could make immunotherapy treatments, specifically checkpoint inhibitors, work for a wider variety of cancer patients. The study, published today in Developmental Cell, found that when the DUX4 gene is expressed in cancer …

Read More »

Roche and GE Launch NAVIFY Tumor Board with Medical Imaging Capabilities to Enable More Personalized Decisions in Cancer Care

Basel, 31 May 2019 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the release of NAVIFY Tumor Board 2.0, the first collaboration product from our partnership with GE Healthcare. Incorporating medical image viewing and storage capabilities with other patient data, the product enables tumour boards – multi-disciplinary teams who …

Read More »

Lantheus Collaborates with NanoMab to Provide a Novel Biomarker for Clinical Development and Management of Immuno-Oncology Therapies

NORTH BILLERICA, Mass.–(BUSINESS WIRE)–Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents, today announced that it has entered into a strategic collaboration and license agreement with NanoMab Technology Limited (“NanoMab”), …

Read More »

Moffitt Cancer Center Partners with TuHURA Biopharma to Develop a New Generation of Targeted Immunotherapies

TAMPA, Fla. and SEATTLE, May 29, 2019 /PRNewswire/ — Moffitt Cancer Center announced today a licensing agreement with TuHURA Biopharma, Inc., a start-up biotechnology company in Seattle, to develop new immunotherapy treatments for cancer that will apply to a greater number of cancers and a larger patient population. This agreement …

Read More »

Early Research Using Blood-Based Methylated DNA Markers Demonstrates a Potential to Achieve 92% Sensitivity and 92% Specificity for Detecting Pancreatic Cancer

SAN DIEGO, May 20, 2019 /PRNewswire/ — Early research using blood-based methylated DNA markers, identified through the longstanding collaboration between Exact Sciences and Mayo Clinic, demonstrates a potential to achieve 92% sensitivity and 92% specificity for detecting the most common type of pancreatic cancer. Researchers presented the findings at Digestive …

Read More »